Arca
Skip to content
Tools
Tools

CSF3R: Granulocyte colony-stimulating factor receptor

Receptor for granulocyte colony-stimulating factor (CSF3), essential for granulocytic maturation.

  • Drugs that act on it: 10
  • Approved: 6
  • In phases 1 to 3: 4
  • Sponsors: 6

Who is on it, and how far along

Every drug ChEMBL records acting on CSF3R, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1
  • Protein or peptide 9

Approved6

  • Filgrastim
  • Lenograstim
  • Lipegfilgrastim
  • Pegfilgrastim
  • Efbemalenograstim alfa
  • Eflapegrastim

Phase 31

  • Regramostim

Phase 23

  • Anumigilimab
  • Balugrastim
  • Pegteograstim

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 9 of 10 act as: Granulocyte colony stimulating factor receptor agonist; the rest name their own mechanism.
    FilgrastimApprovedMerck & Co. (MSD)Protein or peptideAgonist228
    LenograstimApprovedMerck & Co. (MSD)Protein or peptideAgonist227
    LipegfilgrastimApprovedMerck & Co. (MSD)Protein or peptideAgonist64
    PegfilgrastimApprovedMerck & Co. (MSD)Protein or peptideAgonist64
    Efbemalenograstim alfaApprovedEvive BiotechnologyProtein or peptideAgonist3
    EflapegrastimApprovedSpectrum PharmaceuticalsProtein or peptideAgonist1
    RegramostimPhase 3Savara Inc.Protein or peptideAgonist4
    AnumigilimabPhase 2CSLAntibodyAntagonistGranulocyte colony stimulating factor receptor antagonist1
    BalugrastimPhase 2Teva Pharmaceutical IndustriesProtein or peptideAgonist0
    PegteograstimPhase 2—Protein or peptideAgonist0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 24 in all, from ClinicalTrials.gov.
    A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Filgrastim, LenograstimPhase 2 / Phase 3Not yet recruitingMerck Sharp & Dohme LLCNov 5, 2026
    Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric GliomaFilgrastim, Lenograstim, Lipegfilgrastim, PegfilgrastimPhase 2Not yet recruitingSt. Jude Children's Research HospitalNov 4, 2026
    MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)Filgrastim, LenograstimPhase 1 / Phase 2Not yet recruitingMerck Sharp & Dohme LLCNov 2, 2026
    A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia DisordersFilgrastim, LenograstimPhase 2Not yet recruitingX4 PharmaceuticalsOct 29, 2026
    Mecapegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast CancerFilgrastim, Lenograstim—RecruitingZheng YabingOct 27, 2026
    G-CSF In Neonatal Sepsis With NeutropeniaFilgrastim, LenograstimNot applicableNot yet recruitingUniversity of Health Sciences LahoreOct 22, 2026
    A Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety and Tolerability of Filgrastim Biosimilar and Neupogen Reference Product in Healthy VolunteersFilgrastim, LenograstimPhase 1Not yet recruitingBioGeneric PharmaOct 16, 2026
    Study of G-CSF for DOR in Patients Undergoing IVFFilgrastim, LenograstimPhase 4RecruitingCenter for Human ReproductionOct 13, 2026
    Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell MobilizationLipegfilgrastim, PegfilgrastimPhase 2 / Phase 3Not yet recruitingThe Affiliated People's Hospital of Ningbo UniversitySep 30, 2026
    A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)Lipegfilgrastim, PegfilgrastimPhase 3RecruitingMerck Sharp & Dohme LLCSep 21, 2026
    Correlation Between ANC and Bone Pain in Breast Cancer Patients Receiving Long-Acting G-CSFEfbemalenograstim alfa—Not yet recruitingThe First Affiliated Hospital with Nanjing Medical UniversitySep 8, 2026
    A Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of NKF-PEG, and US-Neulasta in Healthy Adult Male VolunteersLipegfilgrastim, PegfilgrastimPhase 1RecruitingNanjing King-Friend Biochemical Pharmaceutical Co., Ltd.Jul 31, 2026
    An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant TherapyLipegfilgrastim, PegfilgrastimNot applicableRecruitingYonsei UniversityApr 13, 2026
    A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)Lipegfilgrastim, PegfilgrastimPhase 3RecruitingMerck Sharp & Dohme LLCFeb 19, 2026
    Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell LymphomasLipegfilgrastim, PegfilgrastimPhase 1RecruitingCity of Hope Medical CenterDec 12, 2025
    Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)AnumigilimabPhase 2RecruitingCSL BehringNov 4, 2025
    Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/LymphomaLipegfilgrastim, PegfilgrastimPhase 2RecruitingUniversity of WashingtonNov 4, 2025
    Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FNEfbemalenograstim alfaPhase 2RecruitingHenan Cancer HospitalSep 23, 2025
    The Safety, Tolerability, and Efficacy of KD01 in Gynecologic MalignanciesRegramostimPhase 1RecruitingTongji HospitalAug 14, 2024
    Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).RegramostimPhase 3RecruitingSavara Inc.May 29, 2024
    Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy RegimenEfbemalenograstim alfaPhase 2RecruitingShandong UniversityFeb 9, 2024
    A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive ChemotherapyEflapegrastimPhase 2RecruitingSpectrum Pharmaceuticals, IncSep 30, 2020
    Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)RegramostimPhase 3Active, not recruitingSavara Inc.Sep 10, 2020
    pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate CancerRegramostimPhase 2Active, not recruitingUniversity of Wisconsin, MadisonJul 26, 2018

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    Autosomal recessive severe congenital neutropenia due to CSF3R deficiency
    0.78
    Neoplasm
    0.63
    Hereditary neutrophilia
    0.62
    Cancer
    0.60
    Severe congenital neutropenia
    0.57
    Infection
    0.53
    HIV infectious disease
    0.51

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1996, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q99062, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.